Evidence map›Paper›PMID 34833310›Full record

ReviewPolymers2021

The Potential Contribution of Biopolymeric Particles in Lung Tissue Regeneration of COVID-19 Patients.

Mohamed Abbas, Mohammed S Alqahtani, Hussain M Almohiy, Fawaz F Alqahtani, Roaa Alhifzi, Layal K Jambi

Abstract readReview
In one paragraph

Review in Polymers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohamed AbbasElectrical Engineering Department, College of Engineering, King Khalid University, Abha 61421, Saudi Arabia.ORCID 0000-0002-3141-2900
Mohammed S AlqahtaniRadiological Sciences Department, College of Applied Medical Sciences, King Khalid University, Abha 61421, Saudi Arabia.
Hussain M AlmohiyRadiological Sciences Department, College of Applied Medical Sciences, King Khalid University, Abha 61421, Saudi Arabia.
Fawaz F AlqahtaniDepartment of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran 1988, Saudi Arabia.ORCID 0000-0003-1494-0303
Roaa AlhifziRadiological Sciences Department, College of Applied Medical Sciences, King Khalid University, Abha 61421, Saudi Arabia.
Layal K JambiRadiological Sciences Department, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia.

Funding

King Khalid University (RGP.1/99/42)
6 · The paper itself

Abstract

The lung is a vital organ that houses the alveoli, which is where gas exchange takes place. The COVID-19 illness attacks lung cells directly, creating significant inflammation and resulting in their inability to function. To return to the nature of their job, it may be essential to rejuvenate the afflicted lung cells. This is difficult because lung cells need a long time to rebuild and resume their function. Biopolymeric particles are the most effective means to transfer developing treatments to airway epithelial cells and then regenerate infected lung cells, which is one of the most significant symptoms connected with COVID-19. Delivering biocompatible and degradable natural biological materials, chemotherapeutic drugs, vaccines, proteins, antibodies, nucleic acids, and diagnostic agents are all examples of these molecules' usage. Furthermore, they are created by using several structural components, which allows them to effectively connect with these cells. We highlight their most recent uses in lung tissue regeneration in this review. These particles are classified into three groups: biopolymeric nanoparticles, biopolymeric stem cell materials, and biopolymeric scaffolds. The techniques and processes for regenerating lung tissue will be thoroughly explored.

Indexed as

biopolymeric nanoparticlesbiopolymeric scaffoldsCOVID-19lungstem cellstissue regeneration

Identifiers

PMID34833310
PMCPMC8623030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.